Based on the above mentions, we hypothesized that the miR-497/FGF-23 axis also affected cardiotoxicity in breast cancer patients, particular in HER2-positive breast cancer patients treated with neoadjuvant/adjuvant trastuzumab-involved regimens. The gene discussed is FGF23; the disease is breast carcinoma.